Science News
from research organizations

In Alzheimer's mice, memory restored with cancer drug

Date:
March 31, 2015
Source:
Yale University
Summary:
Memory and as well as connections between brain cells were restored in mice with a model of Alzheimer's given an experimental cancer drug, researchers report. "With this treatment, cells under bombardment by beta amyloid plaques show restored synaptic connections and reduced inflammation, and the animal's memory, which was lost during the course of the disease, comes back," said the senior author of the study.
Share:
FULL STORY

Star--like glial cells in red surround alpha beta plaques in the cortex of a mouse with a model of Alzheimer's Disease.
Credit: Image courtesy of Yale University

Memory and as well as connections between brain cells were restored in mice with a model of Alzheimer's given an experimental cancer drug, Yale School of Medicine researchers reported in the journal Annals of Neurology.

The drug, AZD05030, developed by Astra Zeneca proved disappointing in treating solid tumors but appears to block damage triggered during the formation of amyloid-beta plaques, a hallmark of Alzheimer's disease. The new study, funded by an innovative National Institutes of Health (NIH) program to test failed drugs on different diseases, has led to the launch of human trials to test the efficacy of AZD05030 in Alzheimer's patients.

"With this treatment, cells under bombardment by beta amyloid plaques show restored synaptic connections and reduced inflammation, and the animal's memory, which was lost during the course of the disease, comes back," said Stephen M. Strittmatter, the Vincent Coates Professor of Neurology and senior author of the study.

In the last five years, scientists have developed a more complete understanding of the complex chain of events that leads to Alzheimer's disease. The new drug blocks one of those molecular steps, activation of the enzyme FYN, which leads to the loss of synaptic connections between brain cells. Several other steps in the disease process have the potential to be targets for new drugs, Strittmatter said.

"The speed with which this compound moved to human trials validates our New Therapeutic Uses program model and serves our mission to deliver more treatments to more patients more quickly," said Christopher P. Austin, M.D., director of NIH's National Center for Advancing Translational Sciences (NCATS), which funded the work.


Story Source:

Materials provided by Yale University. Original written by Bill Hathaway. Note: Content may be edited for style and length.


Journal Reference:

  1. Adam C. Kaufman, Santiago V. Salazar, Laura T. Haas, Jinhee Yang, Mikhail A. Kostylev, Amanda T. Jeng, Sophie A. Robinson, Erik C. Gunther, Christopher H. van Dyck, Haakon B. Nygaard, Stephen M. Strittmatter. Fyn inhibition rescues established memory and synapse loss in Alzheimer mice. Annals of Neurology, 2015; DOI: 10.1002/ana.24394

Cite This Page:

Yale University. "In Alzheimer's mice, memory restored with cancer drug." ScienceDaily. ScienceDaily, 31 March 2015. <www.sciencedaily.com/releases/2015/03/150331145138.htm>.
Yale University. (2015, March 31). In Alzheimer's mice, memory restored with cancer drug. ScienceDaily. Retrieved March 29, 2017 from www.sciencedaily.com/releases/2015/03/150331145138.htm
Yale University. "In Alzheimer's mice, memory restored with cancer drug." ScienceDaily. www.sciencedaily.com/releases/2015/03/150331145138.htm (accessed March 29, 2017).